Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. tried to get a rehearing en banc regarding the counterclaim provision of the Hatch-Waxman Act (HWA).  Novo Nordisk A/S v. Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind., US Court of Appeals for the Federal Circuit (2010-1001). The petition for panel rehearing and for rehearing en banc was denied. […]

In Takeda v. Mylan (07-1269;70), Alphapharm and Genpharm, along with Mylan and UDL Laboratories, tried to get out of paying the attorney fees.  A district court found the case to be exceptional awarded attorney fees in a case relating to Hatch-Waxman challenges made by Alphapharm and Mylan in connection with Takeda’s U.S. Pat. 4,687,777. The […]